News | May 04, 2021
Glenmark launches Ryaltris-AZ at affordable price
First company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg
First company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
This achievement enables the company to strengthen its presence in the high growth market of South Asian countries
Port chairpersons have been asked to personally supervise logistic operations to ensure unhindered movement of such consignments for berthing of such vessel on top priority in the port
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
Tiger can no longer make an important biotin intermediate using a DSM patented process.
Subscribe To Our Newsletter & Stay Updated
